There are 412 resources available
Invited Discussant LBA68 and LBA69
Presenter: Daniel Shao Weng Tan
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Slides
Webcast
Invited Discussant LBA70 and LBA71
Presenter: Yi-Long Wu
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Slides
Webcast
When and how to combine PD-1/PD-L1?
Presenter: Sanjay Popat
Session: Open questions in immunotherapy for advanced NSCLC: Duration of IO, combinations and rechallenge
Resources:
Slides
Webcast
Invited Discussant 1988MO, 1989MO and 1990MO
Presenter: Andrea Ardizzoni
Session: Mini oral session 1 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
Oncogene-addicted metastatic NSCLC case presentation
Presenter: Mariana Brandão
Session: ESMO Clinical Practice Guidelines 1
Resources:
Slides
Webcast
Who should and shouldn't get surgery?
Presenter: Jonathan Spicer
Session: Managing stage III NSCLC in the era of IO
Resources:
Slides
Webcast
Immunotherapy re-challenge: Who, when and why
Presenter: Natasha Leighl
Session: Open questions in immunotherapy for advanced NSCLC: Duration of IO, combinations and rechallenge
Resources:
Slides
Webcast
How to overcome IO resistance: New approaches
Presenter: Edward Garon
Session: Open questions in immunotherapy for advanced NSCLC: Duration of IO, combinations and rechallenge
Resources:
Slides
Webcast
Perspective from the Chair
Presenter: Tony S.K. Mok
Session: Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: ESMO Colloquium supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca: The impact of antibody-drug conjugates (ADCs) in the changing treatment landscape of advanced NSCLC
Resources:
Webcast